Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Foghorn Therapeutics ( (FHTX) ) has issued an announcement.
Foghorn Therapeutics announced its strategic objectives for 2025, highlighting the progress of its inhibitor and degrader programs. The company is advancing its first-in-class oral selective SMARCA2 inhibitor, FHD-909, in a Phase 1 trial targeting SMARCA4 mutated cancers, particularly non-small cell lung cancer. Foghorn is also making strides in its preclinical pipeline, with successful selective degradation of ARID1B and ongoing development of Selective CBP and EP300 degraders. With a strong balance sheet and cash runway extending into 2027, Foghorn is positioned for significant advancements in its oncology programs.
More about Foghorn Therapeutics
Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing innovative medicines that target genetically determined dependencies in the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company is advancing multiple oncology product candidates.
YTD Price Performance: -6.32%
Average Trading Volume: 156,298
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $239.1M
Find detailed analytics on FHTX stock on TipRanks’ Stock Analysis page.
